Teva Establishes Four Pillars To Prop Up Its Return-To-Growth Strategy

Austedo And Uzedy Key To Near-Term Growth

New CEO Richard Francis outlined the company’s new focus on innovative brands, funded by a portion of capital reallocated from Teva’s generics business.

Four massive columns, blue sky in Barcelona of Spain — Teva's growth pillars will support innovation over generics • Source: Shutterstock

Teva Pharmaceutical Industries Ltd. – a company best known for selling generic drugs – said it will pivot more towards innovative drugs in the future as the headwinds for generic drugs continue to mount.

Teva has been struggling to increase revenue since 2017 but has a new strategy for growth over the next five...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Altimmune’s Phase IIb MASH Data Send Share Price Plunging

27 Jun 2025

• By Joseph Haas

Altimmune’s stock price did not recover on June 27, after a 57% dip the day before, despite efforts to position pemvidutide as both resolving MASH and offering weight loss.

Deal Watch: Novartis To Develop Cardiovascular Therapies With ProFound

27 Jun 2025

• By Joseph Haas, Sushmita Panda, Jung Won Shin, and Alaric DeArment

Plus deals involving BioCryst/Neopharmed Gentili, Sanofi/Kymera, Abion, Denovo/Chuang Yi, Carisma/OrthoCellix, Otsuka/Harbour Biomed, Aptose/Hanmi, Philochem/RayzeBio, Concentra/Elevation Oncology, and more.